Biomedical papers, 2011 (vol. 155), issue 3

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011, 155(3):259-262 | 10.5507/bp.2011.033

HDAC INHIBITORS SODIUM BUTYRATE AND SODIUM VALPROATE DO NOT AFFECT HUMAN NCOR1 AND NCOR2 GENE EXPRESSION IN HL-60 CELLS

Jiri Vrbaa, Katerina Trtkovab, Jitka Ulrichovaa,c
a Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
b Laboratory of Molecular Pathology, Department of Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc
c Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc

Aim: This study was designed to examine whether the class I and class IIa histone deacetylase (HDAC) inhibitors, sodium butyrate and sodium valproate alter the expression of human NCOR1 and/or NCOR2 genes coding for N-CoR (nuclear receptor corepressor) and SMRT (silencing mediator for retinoid and thyroid hormone receptors), respectively.

Methods: Human leukemia HL-60 cells were treated for 24 h with 0.5 and 1 mM sodium butyrate, 1 to 3 mM sodium valproate, 1 mcM all-trans retinoic acid (ATRA) or cotreated with 1 mcM ATRA and 0.5 mM sodium butyrate. The acetylation of histones H3 and H4 was analysed by western blotting. The levels of NCOR1 and NCOR2 mRNA were determined by quantitative real-time PCR. Expression of NCF2 gene coding for the NADPH oxidase subunit p67phox was evaluated as a marker of myeloid differentiation.

Results: Both butyrate and valproate increased the acetylation of histone H3 at Lys9 and/or Lys14 as well as histone H4 at Lys12. Both HDAC inhibitors caused a significant increase in NCF2 mRNA levels without affecting NCOR1 or NCOR2 mRNA levels. Similarly, ATRA alone or in combination with butyrate induced NCF2 gene expression without any significant influence on the expression of NCOR1 or NCOR2 genes.

Conclusion: We conclude that inhibitors of class I and class IIa HDACs do not alter the expression of human NCOR1 or NCOR2 genes and that the onset of myeloid differentiation is not accompanied by induction or repression of these genes in HL-60 cells.

Keywords: Nuclear corepressor, Histone deacetylase, NADPH oxidase, Valproic acid, All-trans retinoic acid, Gene expression, Differentiation

Received: March 21, 2011; Accepted: May 3, 2011; Published: September 1, 2011


References

  1. Auger AP, Jessen HM. Corepressors, nuclear receptors, and epigenetic factors on DNA: a tail of repression. Psycho neuro endo crinology 2009;34 Suppl 1:S39-47.
  2. Karagianni P, Wong J. HDAC3: taking the SMRT-N-CoRrect road to repression. Oncogene 2007;26:5439-5449. Go to original source... Go to PubMed...
  3. Stanya KJ, Kao HY. New insights into the functions and regulation of the transcriptional corepressors SMRT and N-CoR. Cell Div 2009;4:7. Go to original source... Go to PubMed...
  4. Ozpolat B. Acute promyelocytic leukemia and differentiation therapy: molecular mechanisms of differentiation, retinoic acid resistance and novel treatments. Turk J Hematol 2009;26:47-61.
  5. Minucci S, Nervi C, Lo Coco F, Pelicci PG. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 2001;20:3110-3115. Go to original source... Go to PubMed...
  6. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: What are the cancer relevant targets? Cancer Lett 2009;277:8-21. Go to original source... Go to PubMed...
  7. Frasor J, Danes JM, Funk CC, Katzenellenbogen BS. Estrogen down-regulation of the corepressor N-CoR: mechanism and implications for estrogen derepression of N-CoR-regulated genes. Proc Natl Acad Sci U S A 2005;102:13153-13157. Go to original source... Go to PubMed...
  8. Misiti S, Schomburg L, Yen PM, Chin WW. Expression and hormonal regulation of coactivator and corepressor genes. Endocrinology 1998;139:2493-2500. Go to original source... Go to PubMed...
  9. Dunlop TW, Vaisanen S, Frank C, Carlberg C. The genes of the coactivator TIF2 and the corepressor SMRT are primary 1,25(OH)2D3 targets. J Steroid Biochem Mol Biol 2004;89-90:257- 260. Go to original source... Go to PubMed...
  10. Macejova D, Dvorak Z, Vrzal R, Ulrichova J, Ondkova S, Brtko J. The effect of all-trans retinoic acid and/or colchicine on expression of rexinoid and thyroid hormone nuclear receptors and their coregulators in primary rat hepatocytes. Gen Physiol Biophys 2007;26:240-242. Go to PubMed...
  11. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007;26:5541-5552. Go to original source... Go to PubMed...
  12. Vrba J, Dolezel P, Ulrichova J. Neutrophilic differentiation modulates the apoptotic response of HL-60 cells to sodium butyrate and sodium valproate. Neoplasma 2010;57:438-448. Go to original source... Go to PubMed...
  13. Collins SJ. The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. Blood 1987;70:1233-1244. Go to PubMed...
  14. Cheng YC, Lin H, Huang MJ, Chow JM, Lin S, Liu HE. Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia. Leuk Res 2007;31:1403-1411. Go to original source... Go to PubMed...
  15. Miyamoto D, Someya A, Nunoi H, Nagaoka I, Yamashita T. Analysis of the NADPH oxidase components during differentiation of HL-60 cells to eosinophilic lineage. Biochim Biophys Acta 1994;1224:11-16. Go to original source... Go to PubMed...
  16. Davie JR. Inhibition of histone deacetylase activity by butyrate. J Nutr 2003;133:2485S-2493S. Go to PubMed...
  17. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 2004;64:1079-1086. Go to original source... Go to PubMed...
  18. Dalton WT, Jr., Ahearn MJ, McCredie KB, Freireich EJ, Stass SA, Trujillo JM. HL-60 cell line was derived from a patient with FAB-M2 and not FAB-M3. Blood 1988;71:242-247. Go to PubMed...
  19. Jing Y, Xia L, Waxman S. Targeted removal of PML-RAR protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia. Blood 2002;100:1008-1013. Go to original source... Go to PubMed...
  20. Melnick A, Licht JD. Deconstructing a disease: RAR, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999;93:3167-3215. Go to PubMed...